Medical management of primary hyperparathyroidism
Arch. endocrinol. metab. (Online)
;
66(5): 689-693, Sept.-Oct. 2022. tab
Article
Dans Anglais
|
LILACS-Express
| LILACS
| ID: biblio-1420074
ABSTRACT
ABSTRACT Primary hyperparathyroidism (PHPT) is an endocrine disorder resulting from the hyperfunction of one or more parathyroid glands, with hypersecretion of parathyroid hormone (PTH). It can be managed by parathyroidectomy (PTX) or non-surgically. Medical therapy with pharmacological agents is an alternative for those patients with asymptomatic PHPT who meet guidelines for surgery but are unable or unwilling to undergo PTX. In this review, we focus upon these non-surgical aspects of PHPT management. We emphasize the most studied and widely used pharmacological alternatives bisphosphonates, denosumab, cinacalcet and hormone therapy, in addition to combined therapy. We also address the relevant aspects of perioperative management.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Type d'étude:
Guide de pratique
langue:
Anglais
Texte intégral:
Arch. endocrinol. metab. (Online)
Thème du journal:
Endocrinologie
/
Métabolisme
Année:
2022
Type:
Article
Pays d'affiliation:
Brésil
/
États-Unis d'Amérique
Institution/Pays d'affiliation:
Columbia University/US
/
Universidade de Pernambuco/BR
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS